Gram-negative

Mutabilis is a biotechnology company focused on the development of novel chemical entities to treat MDR Gram-negative bacterial infections. Mutabilis’ team has a unique expertise in diazabicyclooctane chemistry and its applications in the discovery of novel antibacterials and beta-lactamase inhibitors, inherited from the former Novexel company that contributed to the development of Avibactam. With outstanding stability to hydrolysis by serine- and metallo-beta-lactamases, diazabicyclooctane derivatives are particularly promising to address the most difficult infections, namely those that are resistant to carbapenems.